-+ 0.00%
-+ 0.00%
-+ 0.00%

This ASX 200 share has fallen almost 50%. Is it a bargain for 2027?

The Motley Fool·11/20/2026 22:00:00
Listen to the news

A well-known S&P/ASX 200 Index (ASX: XJO) share has fallen almost 50% from its 52-week high.

I think that's the kind of decline that can get bargain hunters interested, especially when the business has a strong track record.

But is this an opportunity to buy a quality company at a discount, or should investors remain cautious?

An ASX 200 share under pressure

The company I'm talking about is Cochlear Ltd (ASX: COH).

The hearing implant specialist has had a difficult year, with its shares falling from a 52-week high of approximately $285 to around $150 today.

And there are some understandable reasons for the weakness. Cochlear's FY26 results revealed a 22% decline in underlying net profit to $322 million, while its gross profit margin slipped from 74% to 71%.

Weaker demand in developed markets, higher costs, and currency movements all contributed to the disappointing performance.

However, I think there's a lot more to Cochlear's long-term investment story.

A big opportunity remains

One figure from Cochlear's recent Capital Markets Day caught my eye.

According to management, fewer than 5% of adults in developed markets who could benefit from a cochlear implant currently have one.

That's a huge number of potential patients who could eventually benefit from the company's technology. And Cochlear is exceptionally well positioned to serve this market, holding more than 60% of the global hearing implant market.

I also like the recurring revenue opportunities created by its customer base. Cochlear has helped more than 800,000 people hear through its implantable solutions.

Many of those customers will require replacement sound processors and other services over their lifetimes.

For example, in FY26, this services business generated $635 million in revenue, representing approximately 27% of group sales. I think this provides an attractive foundation for long-term growth.

Could earnings recover in 2027?

Cochlear has already taken steps to address its recent difficulties.

The ASX 200 share is reducing costs, improving patient referral pathways, and expanding access to its latest technology.

Its new Nucleus Nexa implant system has also enjoyed strong adoption, accounting for more than 95% of developed-market implant sales by June.

And there are some early signs of improvement. At its November Capital Markets Day, Cochlear revealed that developed-market implant volumes had increased by a mid-single-digit percentage during the first four months of FY27.

Management continues to forecast underlying net profit of between $330 million and $350 million for FY27.

While that is only a modest recovery, the company's longer-term ambition is to grow underlying earnings by approximately 10% annually.

Would I buy Cochlear shares?

I would be happy to buy Cochlear shares at current levels, although I wouldn't necessarily call them a bargain.

At around $150, the shares still trade on a price-to-earnings (PE) ratio of around 30 times the midpoint of management's forecast FY27 underlying earnings.

That's a premium valuation for a company expecting only modest profit growth this year.

However, I think investors should also consider what Cochlear could achieve beyond FY27.

Its dominant market position, enormous untapped opportunity, and growing services business give it several ways to increase earnings over the coming decade.

If management can return the company to sustained double-digit earnings growth, I think today's valuation could prove reasonable.

Foolish takeaway

I think Cochlear shares are worth buying following their disappointing decline.

The company's recent difficulties haven't changed my view of its long-term potential, and I'm encouraged by the early signs of improving implant demand.

However, I wouldn't expect an immediate return to its previous highs, especially while earnings growth remains subdued. So, patience will be required.

The post This ASX 200 share has fallen almost 50%. Is it a bargain for 2027? appeared first on The Motley Fool Australia.

Motley Fool contributor Grace Alvino has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Cochlear. The Motley Fool Australia has recommended Cochlear. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Motley Fool's purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. 2026